Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis

Oncotarget

Volumn 4, Issue 12, 2013, Pages 2354-2365

  Petrilli, Alejandra M ^a   Bott, Marga ^a   Fernández Valle, Cristina ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Acetylation; AGK2; Merlin; Neurofibromatosis Type2; high throughput screen; SIRT2; Tumor suppressor

Indexed keywords

BETA ACTIN; HIGH MOBILITY GROUP B1 PROTEIN; LACTATE DEHYDROGENASE; LYSINE; MERLIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SIRTUIN 5; SIRTUIN 7;

ACETYLATION; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL CYCLE ARREST; CELL DEATH; CELL VIABILITY; EPENDYMOMA; GENE; GENE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE; MENINGIOMA; NEURILEMOMA; NEUROFIBROMATOSIS; NEUROMODULATION; NF2 GENE; PILOT STUDY; PROTEIN FUNCTION; SCHWANN CELL; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; WILD TYPE;

ACETYLATION; ANIMALS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; GENES, TUMOR SUPPRESSOR; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; NECROSIS; NEUROFIBROMATOSIS 2; NEUROFIBROMIN 2; SCHWANN CELLS; SIGNAL TRANSDUCTION; SIRTUIN 2;

EID: 84891949982     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1422     Document Type: Article

References (46)

1. Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet journal of rare diseases. 2009; 4:16.
2. Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z and Lonser RR. Neurofibromatosis type 2. Lancet. 2009; 373(9679):1974-1986.
3. Fong B, Barkhoudarian G, Pezeshkian P, Parsa AT, Gopen Q and Yang I. The molecular biology and novel treatments of vestibular schwannomas. Journal of neurosurgery. 2011; 115(5):906-914.
4. Kalamarides M, Acosta MT, Babovic-Vuksanovic D, Carpen O, Cichowski K, Evans DG, Giancotti F, Hanemann CO, Ingram D, Lloyd AC, Mayes DA, Messiaen L, Morrison H, North K, Packer R, Pan D, et al. Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting. Acta neuropathologica. 2012; 123(3):369-380.
5. Li W, Cooper J, Karajannis MA and Giancotti FG. Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus. EMBO reports. 2012; 13(3):204-215.
6. Stamenkovic I and Yu Q. Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Current protein&peptide science. 2010; 11(6):471-484.
7. North BJ and Verdin E. Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome biology. 2004; 5(5):224.
8. Hawse WF, Hoff KG, Fatkins DG, Daines A, Zubkova OV, Schramm VL, Zheng W and Wolberger C. Structural insights into intermediate steps in the Sir2 deacetylation reaction. Structure. 2008; 16(9):1368-1377.
9. Beirowski B, Gustin J, Armour SM, Yamamoto H, Viader A, North BJ, Michan S, Baloh RH, Golden JP, Schmidt RE, Sinclair DA, Auwerx J and Milbrandt J. Sir-two-homolog 2 (Sirt2) modulates peripheral myelination through polarity protein Par-3/atypical protein kinase C (aPKC) signaling. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(43):E952-961.
10. North BJ, Marshall BL, Borra MT, Denu JM and Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell. 2003; 11(2):437-444.
11. Vaquero A, Scher MB, Lee DH, Sutton A, Cheng HL, Alt FW, Serrano L, Sternglanz R and Reinberg D. SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes&development. 2006; 20(10):1256-1261.
12. Yang MH, Laurent G, Bause AS, Spang R, German N, Haigis MC and Haigis KM. HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS. Molecular cancer research: MCR. 2013;doi:10.1158/1541-7786.MRC-13-0040-T.
13. Liu L, Arun A, Ellis L, Peritore C and Donmez G. Sirtuin 2 (SIRT2) enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal damage via deacetylating forkhead box O3a (Foxo3a) and activating Bim protein. The Journal of biological chemistry. 2012; 287(39):32307-32311.
14. Narayan N, Lee IH, Borenstein R, Sun J, Wong R, Tong G, Fergusson MM, Liu J, Rovira, II, Cheng HL, Wang G, Gucek M, Lombard D, Alt FW, Sack MN, Murphy E, et al. The NAD-dependent deacetylase SIRT2 is required for programmed necrosis. Nature. 2012; 492(7428):199-204.
15. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet JC, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT and Kazantsev AG. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science. 2007; 317(5837):516-519.
16. Chopra V, Quinti L, Kim J, Vollor L, Narayanan KL, Edgerly C, Cipicchio PM, Lauver MA, Choi SH, Silverman RB, Ferrante RJ, Hersch S and Kazantsev AG. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. Cell reports. 2012; 2(6):1492-1497.
17. He X, Nie H, Hong Y, Sheng C, Xia W and Ying W. SIRT2 activity is required for the survival of C6 glioma cells. Biochemical and biophysical research communications. 2012; 417(1):468-472.
18. Hiratsuka M, Inoue T, Toda T, Kimura N, Shirayoshi Y, Kamitani H, Watanabe T, Ohama E, Tahimic CG, Kurimasa A and Oshimura M. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochemical and biophysical research communications. 2003; 309(3):558-566.
19. Kim HS, Vassilopoulos A, Wang RH, Lahusen T, Xiao Z, Xu X, Li C, Veenstra TD, Li B, Yu H, Ji J, Wang XW, Park SH, Cha YI, Gius D and Deng CX. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer cell. 2011; 20(4):487-499.
20. Li Y, Nie H, Wu D, Zhang J, Wei X and Ying W. Poly(ADP-ribose) polymerase mediates both cell death and ATP decreases in SIRT2 inhibitor AGK2-treated microglial BV2 cells. Neuroscience letters. 2013; 544:36-40.
21. Zhang Y, Au Q, Zhang M, Barber JR, Ng SC and Zhang B. Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity. Biochemical and biophysical research communications. 2009; 386(4):729-733.
22. Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, Woodruff JM, Berns A and Thomas G. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes&development. 2000; 14(13):1617-1630.
23. Petrilli A, Copik A, Posadas M, Chang LS, Welling DB, Giovannini M and Fernandez-Valle C. LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2. Oncogene. 2013; doi:10.1038/onc.2013.320.
24. Thaxton C, Bott M, Walker B, Sparrow NA, Lambert S and Fernandez-Valle C. Schwannomin/merlin promotes Schwann cell elongation and influences myelin segment length. Molecular and cellular neurosciences. 2011; 47(1):1-9.
25. Hung G, Li X, Faudoa R, Xeu Z, Kluwe L, Rhim JS, Slattery W and Lim D. Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2. International journal of oncology. 2002; 20(3):475-482.
26. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, Lipton SA, Malorni W, Nunez G, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell death and differentiation. 2009; 16(1):3-11.
27. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A, Bamber BA, Bassham DC, Bergamini E, Bi X, Biard-Piechaczyk M, Blum JS, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy. 2008; 4(2):151-175.
28. Dryden SC, Nahhas FA, Nowak JE, Goustin AS and Tainsky MA. Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol Cell Biol. 2003; 23(9):3173-3185.
29. Inoue T, Nakayama Y, Yamada H, Li YC, Yamaguchi S, Osaki M, Kurimasa A, Hiratsuka M, Katoh M and Oshimura M. SIRT2 downregulation confers resistance to microtubule inhibitors by prolonging chronic mitotic arrest. Cell Cycle. 2009; 8(8):1279-1291.
30. North BJ and Verdin E. Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. PLoS One. 2007; 2(8):e784.
31. Pandithage R, Lilischkis R, Harting K, Wolf A, Jedamzik B, Luscher-Firzlaff J, Vervoorts J, Lasonder E, Kremmer E, Knoll B and Luscher B. The regulation of SIRT2 function by cyclin-dependent kinases affects cell motility. J Cell Biol. 2008; 180(5):915-929.
32. Nie H, Chen H, Han J, Hong Y, Ma Y, Xia W and Ying W. Silencing of SIRT2 induces cell death and a decrease in the intracellular ATP level of PC12 cells. International journal of physiology, pathophysiology and pharmacology. 2011; 3(1):65-70.
33. Yuan Q, Yang H, Cheng C, Li C, Wu X, Huan W, Sun H, Zhou Z, Wang Y, Zhao Y, Lu X and Shen A. beta-1,4-Galactosyltransferase I involved in Schwann cells proliferation and apoptosis induced by tumor necrosis factor-alpha via the activation of MAP kinases signal pathways. Molecular and cellular biochemistry. 2012; 365(1-2):149-158.
34. Tao T, Ji Y, Cheng C, Yang H, Liu H, Sun L, Qin Y, Yang J, Wang H and Shen A. Tumor necrosis factor-alpha inhibits Schwann cell proliferation by up-regulating Src-suppressed protein kinase C substrate expression. Journal of neurochemistry. 2009; 111(3):647-655.
35. Tang X, Wang Y, Zhou S, Qian T and Gu X. Signaling pathways regulating dose-dependent dual effects of TNF-alpha on primary cultured Schwann cells. Molecular and cellular biochemistry. 2013; 378(1-2):237-246.
36. Dan L, Klimenkova O, Klimiankou M, Klusman JH, van den Heuvel-Eibrink MM, Reinhardt D, Welte K and Skokowa J. The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. Haematologica. 2012; 97(4):551-559.
37. Maxwell MM, Tomkinson EM, Nobles J, Wizeman JW, Amore AM, Quinti L, Chopra V, Hersch SM and Kazantsev AG. The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS. Human molecular genetics. 2011; 20(20):3986-3996.
38. Harting K and Knoll B. SIRT2-mediated protein deacetylation: An emerging key regulator in brain physiology and pathology. European journal of cell biology. 2010; 89(2-3):262-269.
39. Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, Goehle S, Kollipara R, Depinho RA, Gu Y, Simon JA and Bedalov A. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer research. 2006; 66(8):4368-4377.
40. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF and Yao TP. HDAC6 is a microtubule-associated deacetylase. Nature. 2002; 417(6887):455-458.
41. Zuo Q, Wu W, Li X, Zhao L and Chen W. HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin. Oncology reports. 2012; 27(3):819-824.
42. Burns SS, Akhmametyeva EM, Oblinger JL, Bush ML, Huang J, Senner V, Chen CS, Jacob A, Welling DB and Chang LS. Histone deacetylase inhibitor AR-42 differentially affects cell cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth. Cancer Res.2013;73(2):792-803.
43. Bush ML, Oblinger J, Brendel V, Santarelli G, Huang J, Akhmametyeva EM, Burns SS, Wheeler J, Davis J, Yates CW, Chaudhury AR, Kulp S, Chen CS et al. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro Oncol. 2011;13(9):983-99.
44. Jacob A, Oblinger J, Bush ML, Brendel V, Santarelli G, Chaudhury AR, Kulp S, La Perle KM, Chen CS, Chang LS and Welling DB. Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. The Laryngoscope. 2012; 122(1):174-189.
45. Chen CS, Weng SC, Tseng PH, Lin HP and Chen CS. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. The Journal of biological chemistry. 2005; 280(46):38879-38887.
46. Iacovelli J, Lopera J, Bott M, Baldwin E, Khaled A, Uddin N and Fernandez-Valle C. Serum and forskolin cooperate to promote G1 progression in Schwann cells by differentially regulating cyclin D1, cyclin E1, and p27Kip expression. Glia. 2007; 55(16):1638-1647.